Published online before print August 19, 2002, doi: 10.1161/01.CIR.0000027820.66786.CF
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:1219.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes
South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA)
From the Department of Gastroenterology (A.F.M.S., T.M.E., P.R., T.C.N.) and the Department of Cardiological Sciences (J.-C.K., J.P., A.J.C.), St George’s Hospital Medical School, Tooting, London, and the Department of Gastroenterology (M.A.M.), Mayday University Hospital, Thornton Heath, Surrey, UK.
Correspondence to Dr Mike Mendall, Mayday Hospital, London Road, Thornton Heath, Surrey CR7 7YE, UK. E-mail mike.mendall{at}mhc-tr.sthames.nhs.uk
Background— Infection with Helicobacter pylori and Chlamydia pneumoniae is associated with coronary heart disease. We conducted an intervention study using antibiotics against these bacteria in patients with acute coronary syndromes to determine whether antibiotics reduce inflammatory markers and adverse cardiac events.
Methods and Results— Patients (n=325) admitted with acute myocardial infarction or unstable angina (acute coronary syndromes) were randomized to receive a 1-week course of 1 of 3 treatment regimens: (1) placebo; (2) amoxicillin (500 mg twice daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily); or (3) azithromycin (500 mg once daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily). Serum fibrinogen, white cell count, and high-sensitivity C-reactive protein were measured at study entry and at 1, 3, and 12 months during follow-up. Cardiac death and readmission with acute coronary syndrome were considered clinical end points. Patients were followed for 1 year. C-reactive protein levels were reduced (P=0.03) in unstable angina patients receiving amoxicillin, and fibrinogen was reduced in both patient groups receiving antibiotics (P=0.06). There were 17 cardiac deaths and 71 readmissions with acute coronary syndrome. No difference in frequency or timing of end points was observed between the 2 antibiotic groups. At 12 weeks, there was a 36% reduction in all end points in patients receiving antibiotics compared with placebo (P=0.02). This reduction persisted during the 1-year follow-up. Neither C pneumoniae nor H pylori antibody status was significantly related to response to treatment.
Conclusions— Antibiotic treatment significantly reduced adverse cardiac events in patients with acute coronary syndromes, but the effect was independent of H pylori or C pneumoniae seropositivity.
Key Words: infection • inflammation • atherosclerosis • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  W. L. Baker and K. A. Couch Azithromycin for the secondary prevention of coronary artery disease: A meta-analysis Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 830 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Napoli, L. O. Lerman, F. de Nigris, M. Gossl, M. L. Balestrieri, and A. Lerman Rethinking Primary Prevention of Atherosclerosis-Related Diseases Circulation, December 5, 2006; 114(23): 2517 - 2527. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Andraws, J. S. Berger, and D. L. Brown Effects of Antibiotic Therapy on Outcomes of Patients With Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials JAMA, June 1, 2005; 293(21): 2641 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berman, D. Hasdai, E. Raanani, G. P. Georghiou, L. Kapustin, Y. Chepurko, B. A. Vidne, and E. Hochhauser Ex-vivo effect of roxithromycin on human and rat arterial vasoactivity Interactive CardioVascular and Thoracic Surgery, June 1, 2005; 4(3): 232 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Arno, J C Kaski, D A Smith, J P Akiyu, S E Hughes, and C Baboonian Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques Heart, April 1, 2005; 91(4): 521 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Sheehan, P M Kearney, S O Sullivan, C Mongan, E Kelly, and I J Perry Acute coronary syndrome and chronic infection in the Cork coronary care case-control study Heart, January 1, 2005; 91(1): 19 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A Voils, M. E Evans, M. T Lane, R. H Schosser, and R. P Rapp Use of Macrolides and Tetracyclines for Chronic Inflammatory Diseases Ann. Pharmacother., January 1, 2005; 39(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Wells, A. G. Mainous III, and L. M. Dickerson Antibiotics for the Secondary Prevention of Ischemic Heart Disease: A Meta-analysis of Randomized Controlled Trials Arch Intern Med, October 25, 2004; 164(19): 2156 - 2161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ludewig, P. Krebs, and E. Scandella Immunopathogenesis of atherosclerosis J. Leukoc. Biol., August 1, 2004; 76(2): 300 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.W.G Yarnell, C.C Patterson, P.M Sweetnam, and G.D.O Lowe Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies Eur. Heart J., June 2, 2004; 25(12): 1049 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sander, K. Winbeck, J. Klingelhofer, T. Etgen, and B. Conrad Progression of Early Carotid Atherosclerosis Is Only Temporarily Reduced After Antibiotic Treatment of Chlamydia pneumoniae Seropositivity Circulation, March 2, 2004; 109(8): 1010 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Burnett, S. Durrani, E. Stabile, M. Saji, C. W. Lee, T. D. Kinnaird, E. P. Hoffman, and S. E. Epstein Murine Cytomegalovirus Infection Increases Aortic Expression of Proatherosclerotic Genes Circulation, February 24, 2004; 109(7): 893 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kamath and G.Y.H. Lip Fibrinogen: biochemistry, epidemiology and determinants QJM, October 1, 2003; 96(10): 711 - 729. [Full Text] [PDF]
|
|
|
|
|
|
S. V. Pislaru and F. Van de Werf Antibiotic Therapy for Coronary Artery Disease: Can a WIZARD Change It All? JAMA, September 17, 2003; 290(11): 1515 - 1516. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tsirpanlis, S. Chatzipanagiotou, A. Ioannidis, S. Moutafis, C. Poulopoulou, and C. Nicolaou Detection of Chlamydia pneumoniae in peripheral blood mononuclear cells: correlation with inflammation and atherosclerosis in haemodialysis patients Nephrol. Dial. Transplant., May 1, 2003; 18(5): 918 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Grayston Antibiotic Treatment of Atherosclerotic Cardiovascular Disease Circulation, March 11, 2003; 107(9): 1228 - 1230. [Full Text] [PDF]
|
|
|
|
|
|
R. Zahn, S. Schneider, B. Frilling, K. Seidl, U. Tebbe, M. Weber, M. Gottwik, E. Altmann, F. Seidel, J. Rox, et al. Antibiotic Therapy After Acute Myocardial Infarction: A Prospective Randomized Study Circulation, March 11, 2003; 107(9): 1253 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Higgins Chlamydia pneumoniae and Coronary Artery Disease: The Antibiotic Trials Mayo Clin. Proc., March 1, 2003; 78(3): 321 - 332. [Abstract] [PDF]
|
|
|
|
|
|
P. C Kievit and F. W.A Verheugt The Hotline Sessions of the 24th European Congress of Cardiology Eur. Heart J., January 1, 2003; 24(1): 2 - 7. [Full Text] [PDF]
|
|
|
|
|
|
M. V. Kalayoglu, P. Libby, and G. I. Byrne Chlamydia pneumoniae as an Emerging Risk Factor in Cardiovascular Disease JAMA, December 4, 2002; 288(21): 2724 - 2731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Do Antibiotics Reduce the Risk for Coronary Events? Journal Watch Infectious Diseases, September 20, 2002; 2002(920): 3 - 3. [Full Text]
|
|